Legal & General Group Plc Has $302.21 Million Stock Position in Axon Enterprise, Inc $AXON

Key Points

• Legal & General raised its stake to 421,114 shares of Axon (about 0.53% ownership), a position valued at roughly $302.21 million after adding 12,736 shares in the quarter.
• Axon beat estimates last quarter with $2.15 EPS versus $1.60 expected and $796.72M in revenue (up 38.5% YoY), and the stock carries a consensus "Moderate Buy" with an average target of $762.93.
• Despite momentum, the shares trade at a high valuation (PE ~340.5), insiders have recently sold shares (24,634 shares, ≈$13.8M), and analysts warn of potential short‑term profit‑taking and pullbacks.

Legal & General Group Plc grew its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 3.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 421,114 shares of the biotechnology company's stock after purchasing an additional 12,736 shares during the quarter. Legal & General Group Plc owned about 0.53% of Axon Enterprise worth $302,208,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Stone House Investment Management LLC acquired a new position in Axon Enterprise during the third quarter worth $29,000. New Millennium Group LLC acquired a new stake in shares of Axon Enterprise in the third quarter worth about $29,000. Root Financial Partners LLC acquired a new stake in shares of Axon Enterprise in the third quarter worth about $34,000. Darwin Wealth Management LLC bought a new stake in shares of Axon Enterprise during the 2nd quarter worth about $37,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of Axon Enterprise during the 2nd quarter worth about $56,000. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Recent operating momentum and scale: company commentary and filings highlighted robust device and software demand, rising ARR/bookings and accelerating revenue that underpinned the prior rally. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Positive Sentiment: Analyst backing and price-target runway: multiple firms maintain buy/overweight ratings and the median 6‑month target sits well above current levels, giving upside for longer-term holders. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Positive Sentiment: Momentum recap: AXON had climbed nearly 29% over the prior month on strong device/software demand — a factor that supports the bull case if execution continues. Axon Stock Rises 28.6% in a Month: Should Investors Buy or Wait?
• Neutral Sentiment: No meaningful short-interest signal (data shows zero or NaN) — likely a reporting anomaly, so it shouldn’t be interpreted as a fresh bearish catalyst.
• Neutral Sentiment: Third‑party/industry headlines referencing “Axon” (e.g., AppLovin’s “Axon by AppLovin” product and related studies) are unrelated to Axon Enterprise’s business and can confuse coverage — treat those items as industry noise. AppLovin (APP) Is Up 19.5% After Showcasing AXON 2.0 And AI E-commerce Pivot
• Negative Sentiment: Profit‑taking and valuation sensitivity: analysts and market commentary point to a classic post‑earnings retracement after a fast run; high valuation metrics make the stock susceptible to short‑term pullbacks. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Negative Sentiment: Heavy insider selling noted in recent disclosures increases near‑term perceived risk and can sap sentiment even if proceeds are routine. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Negative Sentiment: Relative underperformance vs. peers on the day added selling pressure, suggesting short‑term rotation rather than a fresh fundamental shift. Axon Enterprise Inc. stock underperforms Tuesday when compared to competitors

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Piper Sandler cut their price objective on Axon Enterprise from $753.00 to $690.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 25th. Needham & Company LLC decreased their target price on Axon Enterprise from $870.00 to $600.00 and set a "buy" rating for the company in a research report on Friday, February 20th. William Blair reiterated an "outperform" rating on shares of Axon Enterprise in a report on Tuesday, February 3rd. Barclays dropped their price target on shares of Axon Enterprise from $702.00 to $682.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 25th. Finally, Northcoast Research upgraded shares of Axon Enterprise from a "neutral" rating to a "buy" rating and set a $742.00 price objective for the company in a research note on Tuesday, January 6th. Sixteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $762.93.

Axon Enterprise Trading Down 2.3%

Axon Enterprise stock opened at $517.57 on Thursday. Axon Enterprise, Inc has a 52 week low of $396.41 and a 52 week high of $885.91. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53. The firm has a market capitalization of $41.61 billion, a PE ratio of 340.51, a PEG ratio of 11.31 and a beta of 1.46. The business's 50-day simple moving average is $533.80 and its 200-day simple moving average is $613.08.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.55. The firm had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The firm's revenue for the quarter was up 38.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.08 EPS. Equities research analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Activity

In related news, insider Isaiah Fields sold 2,000 shares of the business's stock in a transaction on Friday, February 27th. The shares were sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the transaction, the insider owned 55,588 shares of the company's stock, valued at approximately $29,740,135.88. The trade was a 3.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Jennifer H. Mak sold 1,500 shares of the company's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $573.45, for a total transaction of $860,175.00. Following the transaction, the chief accounting officer owned 12,240 shares of the company's stock, valued at approximately $7,019,028. The trade was a 10.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 24,634 shares of company stock valued at $13,803,095. 4.40% of the stock is owned by company insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.